Released Oct 30, 2019, after the close
10-Q filed Nov 1, 2019, 32 days after period end · 0001493152-19-016324
Q3 2019 · 10-Q
Revenue$4.58M$4.58M −23.7% vs Q3 2018−12.4% vs Q2 2019
Net Income-$351.00K-$351.00K N/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.12-$0.12 N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$316,000N/M
Operating Cash Flowderived$422,000+46.0%
Free Cash Flowderived$390,000+40.3%
Margins · derived
Operating margin-6.9%−13.1 pt vs Q3 2018
Net margin-7.7%−11.4 pt vs Q3 2018
What the release said
The release
Same quarter
| Metric | Q3 2019 | Q3 2018 | Q3 2017 | Q3 2016 |
|---|---|---|---|---|
| Revenue | $4.58M | $6.00M | $5.20M | $5.44M |
| Net Income | -$351.00K | $222.00K | -$184.00K | -$573.00K |
| EPS Diluted | -$0.12 | $0.08 | -$0.07 | -$0.31 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR